# Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica

> **NCT04799262** · PHASE2 · COMPLETED · sponsor: **RenJi Hospital** · enrollment: 14 (actual)

## Conditions studied

- Polymyalgia Rheumatica
- Effect of Drug
- Safety Issues

## Interventions

- **DRUG:** Tofacitinib 5 MG

## Key facts

- **NCT ID:** NCT04799262
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-05-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04799262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04799262, "Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04799262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*